CORRECTION: BioLargo Q2 2021 Earnings Results Webcast and Conference Call Tuesday, August 17, 2021 - 11:00 AM Eastern Time
Back to Newsroom
Mentioned in this Article

CORRECTION: BioLargo Q2 2021 Earnings Results Webcast and Conference Call Tuesday, August 17, 2021 - 11:00 AM Eastern Time

Wednesday, August 11, 2021 9:00 AM
Share this article now
Conference Call

An earlier version of this release incorrectly stated that the event would take place on Wednesday, August 17. The event, in fact, will take place on Tuesday, August 17.

WESTMINSTER, CA / ACCESSWIRE / August 11, 2021 / BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable technologies and full-service environmental engineering company to host investor webcast and conference call on Tuesday August 17, 2021, at 8:00 am PST / 11:00 am EST, open to the public. A webcast and conference call will be held to review the company's financial results, discuss recent events, and conduct a question-and-answer session.

The webcast, accompanying presentation materials, and teleconference replay will be made available on the Investor Relations section of BioLargo's website at To listen to a live broadcast, go to the site at least 15 minutes prior to the scheduled start time to register, download, and install any necessary audio video software.

To participate in the live webcast and teleconference:

Webcast Link:
Teleconference Domestic:844-602-0380
Teleconference International:862-298-0970

To watch or listen to a replay of the webcast or teleconference:

Webcast Replay Expiration:Tuesday, August 17, 2022
Teleconference Replay Expiration:Tuesday, August 31, 2021
Teleconference Replay Domestic:877-481-4010
Teleconference Replay International:919-882-2331
Replay Passcode:42482

About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) invents, develops, and commercializes innovative platform technologies to solve challenging environmental problems like PFAS contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. With over 13 years of extensive R&D, BioLargo holds a wide array of issued patents, maintains a robust pipeline of products, and provides full-service environmental engineering. Our peer-reviewed scientific approach allows us to invent or acquire novel technologies and develop them to maturity through our operating subsidiaries. With a keen emphasis on collaborations with academic, municipal, and commercial organizations and associations, BioLargo has proven itself with over 80 awarded grants and numerous pilot projects. We monetize through direct sales, recurring service contracts, licensing agreements, strategic joint venture formation and/or the sale of the IP. Several of our technologies are commercially available and are advancing as disrupters in their respective markets. See our website at

Contact Information

Dennis P. Calvert
President and CEO, BioLargo, Inc.

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo's (the "Company") expectations regarding the impact of the COVID-19 pandemic; anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of the COVID-19 pandemic on the Company's business, results of operations, financial condition, and stock price; the effect of regional economic conditions on the Company's business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company's products. More information on these risks and other potential factors that could affect the Company's business and financial results is included in the Company's filings with the SEC, including in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of the Company's most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

SOURCE: BioLargo, Inc.

BioLargo, Inc.
Back to Newsroom


Copyright 2021 © ACCESSWIRE. All rights reserved. Privacy Policy  |   Terms and Conditions